News

Exclusive-New data show most US patients now stay on Wegovy, Zepbound after a year
By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Hims & Hers Sued Over Wegovy Maker’s Exit, Record Stock Selloff
Hims & Hers Health Inc. investors have sued the telehealth provider days after Novo Nordisk A/S announced it was ending the ...
Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy
Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...
Wegovy: The price, perks, and pitfalls of India’s new weight-loss craze
Wegovy, the ₹26K/month weight-loss jab, hits India with bold promises—from fat loss to heart health. But is this pharma fix a ...
Explained: Everything you need to know ahead of Wegovy's NZ arrival
The count-down's on for New Zealand chemist sales of weight-loss drug Wegovy. A pharmacist has told our newsroom the ...
New data show most patients now stay on Wegovy, Zepbound after a year
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...
Strict criteria Brits need to fit in order to be eligible for Wegovy from NHS
NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...